LUCERNE

E822410

LUCERNE is a large phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.

All labels observed (1)

Label Occurrences
LUCERNE canonical 3

How this entity was disambiguated

Statements (13)

Predicate Object
instanceOf clinical trial
phase III clinical trial
evaluates efficacy of faricimab
faricimab
safety of faricimab
hasConditionCategory age-related macular degeneration
retinal disease
hasPhase Phase III
hasPrimaryIndication neovascular age-related macular degeneration
wet age-related macular degeneration
hasTherapeuticArea ophthalmology
studies treatment of neovascular (wet) age-related macular degeneration
usesIntervention faricimab

How these facts were elicited

Referenced by (3)

Full triples — surface form annotated when it differs from this entity's canonical label.

faricimab clinicalTrial LUCERNE
Vabysmo clinicalTrial LUCERNE
TENAYA relatedTrial LUCERNE